Abstract
Oral glutamine challenge is a test which aims to measure increase in blood ammonia after glutamine intake, what is similar to the situation that occurs after a protein meal. Oral glutamine challenge induces an increase in blood ammonia in patients with cirrhosis but not in healthy control or transplanted subjects. A pathological response curve for glutamine tolerance is defined as an ammonia rise to 128 mg/dl at 60 min after the glutamine ingestion. No serious adverse effects have been described in the different published studies. Oral glutamine challenge is able to predict minimal hepatic encephalopathy, as well as is associated with a poor survival. On the other hand, ammonia is mainly produced by glutaminase. Therefore, glutaminase enzyme is an excellent target to develop new drugs that reduced its activity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kovacevic Z, McGivan JD. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev. 1983;63(2):547–605.
Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPS. Hepatology. 2002;36(5):1163–71.
Oppong KN, Al-Mardini H, Thick M, Record CO. Oral glutamine challenge in cirrhotics pre- and post-liver transplantation: a psychometric and analyzed EEG study. Hepatology. 1997;26(4):870–6.
Romero-Gomez M, Jover M, Diaz-Gomez D, de Teran LC, Rodrigo R, Camacho I, et al. Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis. World J Gastroenterol. 2006;12(15):2406–11.
Romero-Gómez M, Jover M, Del Campo JA, Royo JL, Hoyas E, Galán JJ, et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann Intern Med. 2010;153(5):281–8.
Romero-Gómez M, Grande L, Camacho I, Benitez S, Irles JA, Castro M. Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol. 2002;37(6):781–7.
Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán LC, Corpas R, Camacho I, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol. 2004;41(1):49–54.
Ditisheim S, Giostra E, Burkhard PR, Goossens N, Mentha G, Hadengue A, et al. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol. 2011;11:134.
Romero-Gómez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology. 2004;39(4):939–43.
Huizenga JR, Gips CH, Conn HO, Jansen PL. Determination of ammonia in ear-lobe capillary blood is an alternative to arterial blood ammonia. Clin Chim Acta. 1995;239(1):65–70.
Ortiz M, Córdoba J, Alonso J, Rovira A, Quiroga S, Jacas C, et al. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. J Hepatol. 2004;40(3):552–7.
Miquel M, Bartolí R, Odena G, Serafín A, Cabré E, Galan A, et al. Rat CCl(4)-induced cirrhosis plus total portal vein ligation: a new model for the study of hyperammonaemia and brain oedema. Liver Int. 2010;30(7):979–87.
Mínguez B, García-Pagán JC, Bosch J, Turnes J, Alonso J, Rovira A, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006;43(4):707–14.
Masini A, Efrati C, Merli M, Attili AF, Amodio P, Ceccanti M, et al. Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of nonabsorbable disaccharides on small intestine ammonia generation. Am J Gastroenterol. 1999;94(11):3323–7.
Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998;13(2):147–57.
Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut. 2000;47(4):571–4.
Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992;16(1):138–44.
Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol. 2000;95(12):3574–8.
Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero Mdel M, Maraver M, del Campo JA, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One. 2012;7(11):e49279. doi:10.1371/journal.pone.0049279.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ampuero, J., Romero-Gómez, M. (2015). The Oral Glutamine Challenge in Liver Cirrhosis. In: Rajendram, R., Preedy, V., Patel, V. (eds) Glutamine in Clinical Nutrition. Nutrition and Health. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1932-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1932-1_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1931-4
Online ISBN: 978-1-4939-1932-1
eBook Packages: MedicineMedicine (R0)